{"id":57078,"date":"2026-02-13T13:24:02","date_gmt":"2026-02-13T05:24:02","guid":{"rendered":"https:\/\/flcube.com\/?p=57078"},"modified":"2026-02-13T13:24:03","modified_gmt":"2026-02-13T05:24:03","slug":"china-medical-system-licenses-teikokus-lidoderm-for-postherpetic-neuralgia-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57078","title":{"rendered":"China Medical System Licenses Teikoku\u2019s Lidoderm for Postherpetic Neuralgia in China"},"content":{"rendered":"\n

China Medical System Holdings Limited<\/strong> (HKG:\u202f0867<\/a><\/strong>) announced a licensing agreement<\/strong> with Teikoku Seiyaku Co., Ltd.<\/strong>, securing exclusive distribution rights<\/strong> for Lidoderm (lidocaine gel patch)<\/strong> in Mainland China<\/strong>. The 5% lidocaine patch<\/strong>, FDA-approved since 1999<\/strong> for postherpetic neuralgia (PHN)<\/strong> and marketed in the EU as Versatis (2007)<\/strong>, received China marketing authorization in 2024<\/strong>, addressing a significant unmet need<\/strong> in neuropathic pain management<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensee<\/strong><\/td>China Medical System Holdings Limited (HKG:\u202f0867)<\/td><\/tr>
Licensor<\/strong><\/td>Teikoku Seiyaku Co., Ltd. (Japan)<\/td><\/tr>
Product<\/strong><\/td>Lidoderm (5% lidocaine gel patch)<\/td><\/tr>
Territory<\/strong><\/td>Mainland China (exclusive distribution)<\/td><\/tr>
Manufacturing<\/strong><\/td>Teikoku Seiyaku (supply responsibility)<\/td><\/tr>
Indication<\/strong><\/td>Postherpetic neuralgia (PHN)<\/td><\/tr>
Global Approvals<\/strong><\/td>US FDA (1999); EU EMA as Versatis (2007); China NMPA (2024)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Feature<\/th>Lidoderm Specification<\/th>Clinical Advantage<\/th><\/tr><\/thead>
Active Ingredient<\/strong><\/td>5% lidocaine<\/strong><\/td>Local anesthetic; well-established safety profile<\/td><\/tr>
Mechanism<\/strong><\/td>Voltage-gated sodium channel blockade<\/strong><\/td>Reduces ectopic impulses in primary afferent nerves<\/strong> following injury<\/td><\/tr>
Delivery<\/strong><\/td>Topical gel patch<\/strong><\/td>Targeted, localized pain relief<\/strong>; minimal systemic absorption<\/td><\/tr>
Indication<\/strong><\/td>Postherpetic neuralgia (PHN)<\/strong><\/td>Neuropathic pain<\/strong> following herpes zoster (shingles)<\/td><\/tr>
Clinical Validation<\/strong><\/td>Supported by domestic and international guidelines\/consensus<\/strong><\/td>Standard of care<\/strong> for PHN; reimbursement pathway clarity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Positioning<\/h2>\n\n\n\n
Factor<\/th>Market Analysis<\/th><\/tr><\/thead>
PHN Burden in China<\/strong><\/td>~1 million new PHN cases annually<\/strong> following >3 million shingles cases<\/strong>; aging population<\/strong> drives incidence increase<\/strong><\/td><\/tr>
Neuropathic Pain Gap<\/strong><\/td>Limited effective topical options<\/strong>; oral gabapentinoids<\/strong> (gabapentin, pregabalin) have systemic side effects<\/strong> (sedation, dizziness, weight gain)<\/td><\/tr>
Lidoderm Differentiation<\/strong><\/td>First and only FDA-approved topical PHN therapy<\/strong>; localized efficacy without CNS effects<\/strong>; elderly-friendly<\/strong> (no drug interactions)<\/td><\/tr>
CMS Commercial Strength<\/strong><\/td>Established hospital and retail pharmacy network<\/strong>; pain management and neurology specialist relationships<\/strong>; NRDL negotiation expertise<\/strong><\/td><\/tr>
Teikoku Manufacturing<\/strong><\/td>Japanese quality standards<\/strong>; consistent supply<\/strong>; regulatory compliance<\/strong> with China GMP requirements<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regulatory & Commercial Roadmap<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Licensing agreement execution; importation and distribution setup<\/td>Q1 2026<\/td><\/tr>
Launch<\/strong><\/td>Hospital formulary access; pain specialist education; retail pharmacy distribution<\/td>Q2-Q3 2026<\/td><\/tr>
Reimbursement<\/strong><\/td>NRDL inclusion negotiation for PHN indication<\/td>2026-2027<\/td><\/tr>
Market Expansion<\/strong><\/td>Potential label expansion to other neuropathic pain indications<\/td>Post-approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Lidoderm commercial launch timelines in China, NRDL reimbursement outcomes, and postherpetic neuralgia market penetration. Actual results may differ due to competitive dynamics with generic lidocaine patches, physician prescribing habits for oral neuropathic pain agents, and pricing pressure from national procurement programs.-Fineline Info & Tech<\/a><\/p>\n\n\n\n